Literature DB >> 10699277

Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo.

N Malik1, R Wiwattanapatapee, R Klopsch, K Lorenz, H Frey, J W Weener, E W Meijer, W Paulus, R Duncan.   

Abstract

Dendrimers are highly branched macromolecules of low polydispersity that provide many exciting opportunities for design of novel drug-carriers, gene delivery systems and imaging agents. They hold promise in tissue targeting applications, controlled drug release and moreover, their interesting nanoscopic architecture might allow easier passage across biological barriers by transcytosis. However, from the vast array of structures currently emerging from synthetic chemistry it is essential to design molecules that have real potential for in vivo biological use. Here, polyamidoamine (PAMAM, Starburst), poly(propyleneimine) with either diaminobutane or diaminoethane as core, and poly(ethylene oxide) (PEO) grafted carbosilane (CSi-PEO) dendrimers were used to study systematically the effect of dendrimer generation and surface functionality on biological properties in vitro. Generally, dendrimers bearing -NH(2) termini displayed concentration- and in the case of PAMAM dendrimers generation-dependent haemolysis, and changes in red cell morphology were observed after 1 h even at low concentrations (10 microg/ml). At concentrations below 1 mg/ml CSi-PEO dendrimers and those dendrimers with carboxylate (COONa) terminal groups were neither haemolytic nor cytotoxic towards a panel of cell lines in vitro. In general, cationic dendrimers were cytotoxic (72 h incubation), displaying IC(50) values=50-300 microg/ml dependent on dendrimer-type, cell-type and generation. Preliminary studies with polyether dendrimers prepared by the convergent route showed that dendrimers with carboxylate and malonate surfaces were not haemolytic at 1 h, but after 24 h, unlike anionic PAMAM dendrimers they were lytic. Cationic 125I-labelled PAMAM dendrimers (gen 3 and 4) administered intravenously (i.v.) to Wistar rats ( approximately 10 microg/ml) were cleared rapidly from the circulation (<2% recovered dose in blood at 1 h). Anionic PAMAM dendrimers (gen 2.5, 3.5 and 5.5) showed longer circulation times ( approximately 20-40% recovered dose in blood at 1 h) with generation-dependent clearance rates; lower generations circulated longer. For both anionic and cationic species blood levels at 1 h correlated with the extent of liver capture observed (30-90% recovered dose at 1 h). 125I-Labelled PAMAM dendrimers injected intraperitoneally were transferred to the bloodstream within an hour and their subsequent biodistribution mirrored that seen following i.v. injection. Inherent toxicity would suggest it unlikely that higher generation cationic dendrimers will be suitable for parenteral administration, especially if they are to be used at a high dose. In addition it is clear that dendrimer structure must also be carefully tailored to avoid rapid hepatic uptake if targeting elsewhere (e.g. tumour targeting) is a primary objective.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10699277     DOI: 10.1016/s0168-3659(99)00246-1

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  193 in total

1.  Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor.

Authors:  Antonio Quintana; Ewa Raczka; Lars Piehler; Inhan Lee; Andrzej Myc; Istvan Majoros; Anil K Patri; Thommey Thomas; James Mulé; James R Baker
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

2.  Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: a potential oral delivery system?

Authors:  R Wiwattanapatapee; B Carreño-Gómez; N Malik; R Duncan
Journal:  Pharm Res       Date:  2000-08       Impact factor: 4.200

3.  Structure-skin permeability relationship of dendrimers.

Authors:  Venkata Vamsi Venuganti; Preety Sahdev; Michael Hildreth; Xiangming Guan; Omathanu Perumal
Journal:  Pharm Res       Date:  2011-06-02       Impact factor: 4.200

4.  Enhanced gene and siRNA delivery by polycation-modified mesoporous silica nanoparticles loaded with chloroquine.

Authors:  Shanta Raj Bhattarai; Elayaraja Muthuswamy; Amit Wani; Michal Brichacek; Antonio L Castañeda; Stephanie L Brock; David Oupicky
Journal:  Pharm Res       Date:  2010-08-21       Impact factor: 4.200

Review 5.  Designing dendrimers for drug delivery and imaging: pharmacokinetic considerations.

Authors:  Wassana Wijagkanalan; Shigeru Kawakami; Mitsuru Hashida
Journal:  Pharm Res       Date:  2010-12-23       Impact factor: 4.200

6.  Poly(amidoamine) dendrimer-drug conjugates with disulfide linkages for intracellular drug delivery.

Authors:  Yunus E Kurtoglu; Raghavendra S Navath; Bing Wang; Sujatha Kannan; Robert Romero; Rangaramanujam M Kannan
Journal:  Biomaterials       Date:  2009-01-25       Impact factor: 12.479

7.  Salt intake augments hypotensive effects of transient receptor potential vanilloid 4: functional significance and implication.

Authors:  Feng Gao; Dexin Sui; R Michael Garavito; R Mark Worden; Donna H Wang
Journal:  Hypertension       Date:  2008-12-15       Impact factor: 10.190

8.  Enhanced cellular uptake of a triplex-forming oligonucleotide by nanoparticle formation in the presence of polypropylenimine dendrimers.

Authors:  Latha M Santhakumaran; Thresia Thomas; T J Thomas
Journal:  Nucleic Acids Res       Date:  2004-04-15       Impact factor: 16.971

9.  A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas.

Authors:  Cameron C Lee; Elizabeth R Gillies; Megan E Fox; Steven J Guillaudeu; Jean M J Fréchet; Edward E Dy; Francis C Szoka
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-30       Impact factor: 11.205

Review 10.  Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats.

Authors:  Michelle Longmire; Peter L Choyke; Hisataka Kobayashi
Journal:  Nanomedicine (Lond)       Date:  2008-10       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.